- Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania.
- The facility will produce next-generation weight-loss medicines, including retatrutide.
- Construction begins in 2026, with operations expected to start in 2031.
- The project will create over 2,800 jobs, including 850 high-value positions.
Investment and Purpose
Eli Lilly and Company plans to invest over $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania. This site will focus on producing next-generation injectable weight-loss medicines, including retatrutide, a triple hormone receptor agonist.
Job Creation and Economic Impact
The project is expected to create more than 2,800 jobs, including 850 high-value positions for engineers, scientists, and technicians. Construction will generate 2,000 jobs, and the facility is projected to stimulate local economic activity, with each dollar invested potentially generating four additional dollars in the region.
Timeline and Location
Construction is set to begin in 2026, with the facility becoming operational by 2031. The site in Fogelsville, Pennsylvania, was chosen for its proximity to STEM universities, existing infrastructure, and favorable zoning and incentives.
Technological Advancements and Partnerships
Lilly will employ advanced technologies such as AI, machine learning, and data analytics to ensure efficient operations. The company will also partner with local universities and invest in education to develop talent in Pennsylvania.
